Johnson & Johnson (NYSE:JNJ) had a busy Saturday. The healthcare giant rolled out encouraging clinical updates across two major immunology programs at the American College of Rheumatology (ACR) Convergence 2026, presenting positive Phase 3 data for ICOTYDE in psoriatic arthritis and fresh patient experience insights for nipocalimab in Sjögren's disease.

ICOTYDE Clears The Bar In Phase 3 Psoriatic Arthritis Trial

In the Phase 3 ICONIC-PsA 1 study, which enrolled biologic-naïve adults with active psoriatic arthritis, oral peptide ICOTYDE (icotrokinra) met its primary endpoint at Week 16. ICOTYDE is the first and only targeted therapy to selectively block the IL-23 receptor.

About 58% of patients receiving a 200 mg dose reached an American College of Rheumatology 20 (ACR20) response, compared to 41% on placebo. Patients also attained higher ACR50 (29% versus 16%) and ACR70 (13% versus 5%) response rates.

Among participants with qualifying baseline skin involvement, 57% receiving ICOTYDE achieved clear or almost clear skin versus 14% on placebo, while 37% achieved a PASI 90 score compared to 6% in the control arm.

Clinical gains kept building through Week 24, with ACR20 reaching 69%, ACR50 hitting 40%, and clear skin rates rising to 64%. Across 24 weeks, safety results aligned with the drug's established safety profile, showing no new safety signals.

Nipocalimab Shows Tangible Benefits In Sjögren's Disease

Johnson & Johnson also shared Phase 2 DAHLIAS findings for nipocalimab in Sjögren's disease, an autoantibody-driven illness impacting approximately four million individuals globally.

The data highlighted that mouth dryness represented the most critical symptom improvement for patients, with 96% citing it as their primary complaint. These outcomes build on prior Phase 2 data demonstrating enhanced saliva production.

Patients linked symptom improvements to tangible everyday gains, including enhanced physical functioning and fewer disruptions to work and family life, while 73.5% reported overall satisfaction with the treatment.

Following Phase 2 results showing substantial reductions in disease severity, the company launched the Phase 3 DAFFODIL trial.

JNJ Price Action: Johnson & Johnson shares were up 0.42% at $277.38 at the time of publication on Monday. The stock is trading near its 52-week high of $282.01, according to market data.